-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
-
-
-
-
-
-
-
Morgan Stanley: 'we see Amvuttra as well positioned'
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $460 at BofA Securities
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $529 at BofA Securities
-
-
-
-
-
-
-
Alnylam plans $250 million facility expansion for siRNA manufacturing
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Tops Q3 EPS by $2.38
-
-
-
-
-
-
-
Alnylam secures $500 million revolving credit facility
-
414,072 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

